Introduction {#s1}
============

Due to the aging and growth of population as well as an increasing adoption of cancer-related lifestyle such as smoking and "westernized" diets, cancer has been a major public health problem all around the world [@pone.0102413-Jemal1]. Almost one in four deaths in the United States is related with cancer in 2012 [@pone.0102413-Siegel1]. Lack of efficiently diagnostic and prognostic biomarkers is responsible for the high mortality rates caused by cancer [@pone.0102413-Iorio1].

MicroRNAs (miRNAs), approximately 22 nucleotides in length, are a class of highly conserved RNAs that negatively regulate gene expression at post-transcriptional level by base pairing with the 3′-untranslated region of target mRNAs, resulting in either mRNA degradation or translational inhibition [@pone.0102413-Lee1], [@pone.0102413-Bartel1]. Many studies have demonstrated that miRNAs play important roles in various biological processes, such as cellular development, differentiation, proliferation, cell death, angiogenesis and metabolism [@pone.0102413-Carrington1]--[@pone.0102413-Bartel2]. The success of utilizing miRNAs as diagnostic or prognostic markers from expression profiling has been reported in many studies.

MiR-21 was one of the most frequently studied cancer-related miRNAs and dysregulated in most cancers by acting as oncogene [@pone.0102413-Schee1]--[@pone.0102413-Kumarswamy1]. Up-regulated miR-21 could increase tumor growth, metastasis and invasion and reduce sensitivity to chemotherapy by its various targets [@pone.0102413-SoriaValles1]--[@pone.0102413-Zhou1]. Cancer patients with higher expression of miR-21 always had a worse prognostic outcome. But some studies represented inconsistent or even opposite results, such as the study of Valladares-Ayerbes et al. [@pone.0102413-ValladaresAyerbes1]. So we performed this meta-analysis to reveal the prognostic value of miR-21 in various cancers.

Material and Methods {#s2}
====================

Publication search and inclusion criteria {#s2a}
-----------------------------------------

Medical subheading (Mesh) terms relating to miR-21 (e.g. "miR-21" or "microRNA-21") in combination with words related to cancer (e.g. "cancer", "tumor", "carcinoma" or "neoplasm") and terms to prognosis (e.g. "prognosis", "survival", "outcome" or "prognostic") were searched on PubMed, EMBASE and WEB of science to retrieve eligible studies till December, 2013 .

We also carefully examined the references of articles and reviews to explore potentially additional studies. Studies were eligible if they met the following criteria: (a) studied patients with any type of cancers; (b) expression of miR-21 was measured; (c) the association between expression of miR-21 and clinical outcome was investigated; (d) full text articles in English. Studies were excluded based on the following criteria: (a) reviews, letters or laboratory studies; (b) studies had overlapping or duplicate data; (c) absence of key information for further analysis [@pone.0102413-Tierney1].

Data extraction {#s2b}
---------------

Data were evaluated and extracted independently from the eligible studies by two investigators (Zhou and Wang) under the guidelines of a critical review checklist of the Dutch Cochrane Centre proposed by Meta-analysis of Observational Studies in Epidemiology (MOOSE) [@pone.0102413-Stroup1]. The following items were recorded: first author\'s name, year of publication, country or area of origin, ethnicity, cancer type, sample type, TNM stage, method, total number of patients, cut-off value, follow ups and HRs of miR-21 for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS) or cancer specific survival (CSS) with their 95% confidence intervals (CIs) and P value. If not available, data were extracted by the method of Tierney et al. [@pone.0102413-Tierney1]. When discrepancies existed between the two investigators, another investigator (Huang) was invited to discuss until a consensus was reached.

Statistical analysis {#s2c}
--------------------

All the HRs with their 95% CIs were used to calculate pooled HRs. Cochran\'s Q test and Higgins I-squared statistic were used to check the heterogeneity of pooled results. A P\<0.10 for Q-test suggested significant heterogeneity among studies, and the random-effects model (DerSimonian-Laird method) was applied to calculate the pooled HRs [@pone.0102413-DerSimonian1]. Otherwise, the fixed-effects model (Mantel-Haenszel method) was used [@pone.0102413-Mantel1]. Begg\'s funnel plot and the Egger\'s linear regression test were conducted to evaluate publication bias of literatures and a p\<0.05 was considered significant [@pone.0102413-Egger1]. Trim and fill method was applied to assess potential asymmetry in the funnel plot. Statistical analyses were performed in STATA software version 12.0 (STATA Corporation, College Station, TX, USA). All *P* values were two-sided.

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

After careful read and selection, a total of 63 articles [@pone.0102413-ValladaresAyerbes1], were retrieved according to the inclusion and exclusion criteria. 55 of 63 articles investigated the prognostic role of miR-21 for OS, 17 for DFS, 8 for RFS and 3 for CSS. Schetter et al. [@pone.0102413-Schetter1], Hwang et al. [@pone.0102413-Hwang1] and Akagi et al. [@pone.0102413-Akagi1] presented separate HR by different ethnic background; Mathe et al. [@pone.0102413-Mathe1]\_ENREF_34, Liu et al. [@pone.0102413-Liu2], Toiyama et al. [@pone.0102413-Toiyama1], Nielsen et al. [@pone.0102413-Nielsen1] and Markou et al. [@pone.0102413-Markou2] investigated the role of miR-21 in different type of samples; Voortman et al. [@pone.0102413-Voortman1] reported results from two centers. So the data from these studies were considered separately in our analysis. As there were only 3 studies for CSS, we combined the results for CSS and RFS together as RFS/CSS. Thus, a total of 63 studies including 6720 patients evaluating OS, 19 studies including 1965 cases for DFS and 11 studies including 1696 patients for RFS/CSS were considered in this analysis. The detailed screening process was shown in [Figure 1](#pone-0102413-g001){ref-type="fig"}.

![Methodological flow diagram of the review.](pone.0102413.g001){#pone-0102413-g001}

The main characteristics of eligible studies were listed in [Table 1](#pone-0102413-t001){ref-type="table"}. Ethnicity background of patients were classified as Asian, Caucasian and mixed populations. Cancer types of cases were various, among which lung cancer, pancreatic cancer and gastrointestinal (GI) cancers were mostly investigated. Tissue samples including Frozen or formalin-fixed and paraffin-embedded (FFPE) tissues were used in 53 studies, while 11 studies used circulation samples (plasma, serum or blood) and one study by Ota et al. [@pone.0102413-Ota1] applied bone marrow samples. Quantitative real-time PCR (qRT-PCR) was widely used in 57 studies and in situ hybridisation (ISH) assay was used in the other 6 studies. The most frequently used cut-off value was the median which was applied in 26 studies and the other values ranged from the mean to the highest quarter value.

10.1371/journal.pone.0102413.t001

###### Main characteristics of eligible studies.

![](pone.0102413.t001){#pone-0102413-t001-1}

  Author                  Year       Country           Ethnicity                    Type                    Sample         Stage     Number               Method               Endogenous control          cut-off              Results
  ---------------------- ------ ------------------ ----------------- ---------------------------------- --------------- ----------- --------- ------------------------------- -------------------- ------------------------ ----------------
  **Schetter**            2008        USA/HK        Caucasian/Asian                Colon                 Frozen tissue     I-IV        197                qRT-PCR                      U6              Highest tertile             OS
  **Dillhoff**            2008         USA             Caucasian                 Pancreatic                  FFPE           NR         80          In Situ Hybridization               U6               Highest score              OS
  **Markou**              2008        Greece           Caucasian                   NSCLC                 Frozen tissue     I-IV        48                 qRT-PCR                      U6                   2-fold             OS and DFS
  **Yan**                 2008        China              Asian                     Breast                    FFPE          I-III       113                qRT-PCR                      U6                    Mean                  OS
  **Qian**                2009        Italy            Caucasian                   Breast                Frozen tissue     I-IV        301                qRT-PCR                      U6                     NR               OS and DFS
  **Busacca**             2010        Italy            Caucasian           Malignant mesothelioma            FFPE           NR         24                 qRT-PCR                      U6                   Median                 OS
  **Li**                  2009        China              Asian                     Tongue                Frozen tissue     I-IV        103                qRT-PCR                      U6                   Median                 OS
  **Schetter**            2009        HK/USA        Caucasian/Asian                Colon                 Frozen tissue     I-IV        196                qRT-PCR                      U6              Highest tertile            CSS
  **Mathe**               2009   USA,Canada/Japan   Caucasian/Asian              Esophageal                 Tissue         I-IV        170                qRT-PCR                     U66                   Median                 OS
  **Avissar**             2009         USA             Caucasian                   HNSCC                 Frozen tissue     I-IV        169                qRT-PCR                     U48              Highest quarter             OS
  **Zhi**                 2010        China              Asian                  Astrocytoma              Frozen tissue     I-IV        124                qRT-PCR                    miR-16                 Median                 OS
  **Hu**                  2011         USA             Caucasian                 Esophageal                  FFPE          I-IV        158         In situ hybridization               NR                1--3+/0--0.5          OS and DFS
  **Gao**                 2010        China              Asian                     NSCLC                 Frozen tissue     I-III       47                 qRT-PCR                      U6                   Median                 OS
  **Rossi**               2010         USA             Caucasian                    CLL                      Blood          NR         99                 qRT-PCR                      U6                   Median                 OS
  **Giovannetti**         2010     Netherlands         Caucasian                 Pancreatic                 Tissue         I-IV        59                 qRT-PCR                     U43                   Median             OS and DFS
  **Hwang**               2010     Korea/Italy      Asian/Caucasian              Pancreatic              Frozen tissue     II-IV      82/45               qRT-PCR                   U66/U43                 Median           OS,DFS and RFS
  **Gao**                 2011        China              Asian                      SCLC                 Frozen tissue     I-III       30                 qRT-PCR                      U6                   Median                 OS
  **Kulda**               2010    Czech Republic       Caucasian                    CRC                  Frozen tissue     I-IV        44                 qRT-PCR                      U6                     NR                  DFS
  **Voortman**            2010     14 countries          Mixed                     NSCLC                     FFPE          I-III       631     qRT-PCR/In situ hybridization         U66/U6                 Median                 OS
  **Nielsen**             2011       Denmark           Caucasian                Colon/rectum                 FFPE           II       129/67        In Situ Hybridization               NR                   2-fold                DFS
  **Hamano**              2011        Japan              Asian                   Esophageal                  FFPE          I-IV        98                 qRT-PCR                     U48                   Median                 OS
  **Radojicic**           2011        Greece           Caucasian                   Breast                    FFPE           NR         49                 qRT-PCR                   RNU5A/U6                Median             OS and DFS
  **Ota**                 2011        Japan              Asian                     Breast                 Bone marrow       NR         207                qRT-PCR                      U6                    5.84              OS and DFS
  **Walter**              2011         USA             Caucasian                   Breast                    FFPE           NR         25                 qRT-PCR                      U6                   Median                 OS
  **Saito**               2011   USA/Norway/Japan   Caucasian/Asian                NSCLC                 Frozen tissue     I-II      126/191              qRT-PCR                     U66                   Median              CSS/RFS
  **Shibuya**             2010        Japan              Asian                      CRC                  Frozen tissue   Dukes:A-D     156                qRT-PCR                      U6                    Mean              OS and DFS
  **Liu**                 2012        China              Asian                     NSCLC                 Frozen tissue     I-IV        70                 qRT-PCR                      U6                   2-fold                 OS
  **Wang**                2011        China              Asian                     NSCLC                     Serum         I-III       88                 qRT-PCR                      U6                   5-fold                 OS
  **Ayerbes**             2011        Spain            Caucasian      Colon or rectum/gastric/pancreas       FFPE          I-IV        32                 qRT-PCR                      U6                    Mean                  OS
  **Jiang**               2011        China              Asian                    Gastric                    FFPE         III,IV       55                 qRT-PCR                     U44                     NR                   OS
  **Nagao**               2012        Japan              Asian                   Pancreatic                  FFPE          I-IV        65                 qRT-PCR                      U6                    Mean                  OS
  **Jamieson**            2012          UK             Caucasian                 Pancreatic              Frozen tissue    II-III       72                 qRT-PCR                      U6                   Median                 OS
  **Jiang**               2012        China              Asian                    Melanoma               Frozen tissue     I-IV        86                 qRT-PCR                      U6                   Median             OS and DFS
  **Liu**                 2012        China              Asian                   Pancreatic                  Serum         I-IV        38                 qRT-PCR                      NR                     NR                   OS
  **Karakatsanis**        2013        Greece           Caucasian               Hepatocellular                FFPE          I-IV        60                 qRT-PCR                      U6                    Mean                  OS
  **Gao**                 2012        China              Asian                     NSCLC                 Frozen tissue     I-III       58                 qRT-PCR                      U6                   Median                DFS
  **Lee**                 2011        Korea              Asian                     Breast                    FFPE          I-III       109                qRT-PCR                      U6                    Mean              OS and DFS
  **Li**                  2012        China              Asian                    Prostate                   FFPE         II-III       168         in situ hybridization               NR                  Score\>1               RFS
  **Faltejs kova**        2012    Czech Republic       Caucasian                    CRC                  Frozen tissue     I-IV        44                 qRT-PCR                      U6                   Median                 OS
  **Faragalla**           2012        Canada           Caucasian                   Renal                     FFPE          I-III       89                 qRT-PCR                     U44                     NR               OS and DFS
  **Zaravinos**           2012        Greece           Caucasian                  Bladder                   Tissue          NR         77                 qRT-PCR               RNU1A1,5A and U6            Median             OS and RFS
  **Jung**                2012         USA             Caucasian                    Oral                 Frozen tissue      NR         17                 qRT-PCR                      U6                   Median                 OS
  **Le**                  2012        China              Asian                      Lung                     Serum         I-IV        82                 qRT-PCR                    miR-16                   NR                   OS
  **Xu**                  2012        China              Asian                    Gastric                Frozen tissue     I-IV        86                 qRT-PCR                    Let-7a            ROC curve (AUC)             OS
  **Osawa**               2011        Japan              Asian                    Gastric                    FFPE          I-IV        37                 qRT-PCR                      NR              T/N ratio \>1.40            OS
  **Papaconstantinou**    2013        Greece           Caucasian                 Pancreatic                  FFPE          I-IV        88                 qRT-PCR                      U6                    Mean                  OS
  **Frifeldt**            2012       Denmark           Caucasian                   Colon                     FFPE           II         520         in situ hybridization               NR                  Tertiles            OS and RFS
  **Hermansen**           2013       Denmark           Caucasian                  Gliomas                    FFPE           NR         189         in situ hybridization               NR                     NR                   OS
  **Caponi**              2013       UK/Italy          Caucasian                 Pancreatic                  FFPE         II-III       81                 qRT-PCR                      U6                   Median             OS and DFS
  **Wang**                2013        China              Asian                   Pancreatic                  Serum        III-IV       177                qRT-PCR                      U6                   Median                 OS
  **Komatsu**             2013        Japan              Asian                    Gastric                   Plasma         I-IV        69                 qRT-PCR                      NR                   Median                CSS
  **Amankwah**            2013         USA             Caucasian                  Prostate                   FFPE          I-IV        65                 qRT-PCR                      U6                   median                RFS
  **Chusorn**             2013       Thailand            Asian               Cholangiocarcinoma          Frozen tissue      NR         23                 qRT-PCR                      U6                    Mean                  OS
  **Huang**               2013        China              Asian               Cholangiocarcinoma              FFPE           NR         41                 qRT-PCR                      U6                     NR               OS and RFS
  **Liu**                 2013        China              Asian                      CRC                      Serum         I-IV        166                qRT-PCR                    MiR-16                 0.0043                 OS
  **Akagi**               2013   USA,Norway/Japan   Caucasian/Asian                 Lung                 Frozen tissue     I-II      92/198               qRT-PCR                      NR                   Median             OS and RFS
  **Toiyama**             2013        Japan              Asian                      CRC                   FFPE/serum       I-IV      166/188              qRT-PCR              miR-16/Cel-miR-39       Youden\'s index             OS
  **Bovell**              2013         USA               Mixed                      CRC                      FFPE           IV         55                 qRT-PCR                      U6                     NR                   OS
  **Markou**              2013        Greece           Caucasian                   NSCLC                  FFPE/plasma      I-IV       40/37               qRT-PCR                miR-191/miR-16             Median             OS and DFS
  **Chen**                2013        Taiwan             Asian                      CRC                     Tissue         I-IV        195                qRT-PCR                      U6                    Mean                  OS
  **Ferrajoli**           2013         USA             Caucasian                    CLL                      Blood          NR         93                 qRT-PCR                    miR-16            44th percentile             OS
  **Menendez**            2013        Spain            Caucasian                    CRC                      Serum         I-IV        102                qRT-PCR                    miR-16         Relative expression\>1     OS and DFS
  **Kadera**              2013         USA             Caucasian                 Pancreatic                 Tissue         I-IV        147                qRT-PCR                      U6                     NR                   OS

NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinomas; CLL: chronic lymphocytic leukemia; SCLC: squamous cell lung carcinoma; CRC: colorectal carcinoma; ALL: acute lymphoblastic leukemia NR: not reported; FFPE: formalin-fixed and paraffin-embedded; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; CSS: cancer-specific survival.

Outcomes from eligible studies {#s3b}
------------------------------

The main results of this meta-analysis are shown in [Table 2](#pone-0102413-t002){ref-type="table"}. For 63 studies evaluating OS for miR-21, we found high expression of miR-21 predicting a worse outcome with the combined HR of 1.91 (95%CI: 1.66--2.19; P~heterogeneity~\<0.001; [Figure 2](#pone-0102413-g002){ref-type="fig"}). Similarly predictive roles of miR-21 for DFS and RFS/CSS were also investigated with pooled HR of 1.42 (95% CI: 1.16--1.74; P~heterogeneity~ = 0.001) and 2.2 (95% CI: 1.64--2.96; P~heterogeneity~ = 0.022), respectively.

![Forrest plots of studies evaluating hazard ratios (HRs) of miR-21 for overall survival.](pone.0102413.g002){#pone-0102413-g002}
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###### Meta-analysis results.

![](pone.0102413.t002){#pone-0102413-t002-2}

  Outcome           Variables       Number of studies   Model      HR (95% CI)     P~heterogeneity~
  ------------- ------------------ ------------------- -------- ----------------- ------------------
  **OS**               ALL                 63           Random   1.91(1.66,2.19)       \<0.001
                   Cancer type                                                    
                        GI                 15           Random   1.68(1.12,2.52)       \<0.001
                     Pancreas              11           Random   2.53(1.82,3.51)        0.003
                       Lung                13           Random    1.59(1.2,2.1)        \<0.001
                      Breast                6           Random   2.55(1.04,6.29)        0.002
                       Oral                 2           Random   2.02(0.41,9.88)        0.016
                    Esophagus               4           Random   1.53(0.74,3.15)        0.018
                      Liver                 3           Fixed    1.93(1.39,2.69)        0.688
                    Ethnicity                                                     
                      Asian                29           Random   2.19(1.76,2.73)       \<0.001
                    Caucasian              29           Random   1.86(1.46,2.37)       \<0.001
                      Sample                                                      
                      Tissue               51           Random   1.87(1.61,2.16)       \<0.001
                       FFPE                25           Random   1.68(1.29,2.18)       \<0.001
                  Frozen tissue            23           Random   1.99(1.59,2.49)       \<0.001
                   Circulation             11           Random   2.06(1.42,2.99)        0.008
                      Serum                 8           Random   1.94(1.25,3.03)        0.003
                     Therapy                                                      
                 Adjuvant therapy           7           Random    2.4(1.18,4.9)        \<0.001
                      Mixed                56           Random   1.85(1.61,2.13)       \<0.001
  **DFS**              ALL                 19           Random   1.42(1.16,1.74)        0.001
                   Cancer type                                                    
                        GI                  5           Random   1.12(0.81,1.55)         0.01
                     Pancreas               3           Fixed    2.87(1.89,4.35)        0.524
                       Lung                 4           Fixed    2.05(1.32,3.18)        0.839
                      Breast                4           Fixed    1.1(0.82,1.49)         0.919
                    Ethnicity                                                     
                      Asian                 6           Random   1.62(1.06,2.47)        0.008
                    Caucasian              14           Random   1.37(1.07,1.76)        0.006
  **RFS/CSS**          ALL                 11           Random   2.2(1.64,2.96)         0.022
                   Cancer type                                                    
                        GI                  3           Random    2.5(1.1,5.71)         0.005
                       Lung                 3           Fixed    2.25(1.57,3.23)        0.605
                     Prostate               2           Fixed    2.04(1.17,3.54)        0.957
                    Ethnicity                                                     
                      Asian                 5           Fixed    2.17(1.52,3.09)        0.322
                    Caucasian               5           Random   2.1(1.34,3.27)         0.065

OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; CSS: cancer-specific survival; GI: gastrointestinal; FFPE: formalin-fixed and paraffin-embedded.

Subgroup analyses by cancer type showed that elevated miR-21 yielded a worse OS in GI cancers (HR = 1.68, 95%CI: 1.12--2.52; P~heterogeneity~\<0.001), lung cancer (HR = 1.59, 95%CI: 1.2--2.1; P~heterogeneity~\<0.001), breast cancer (HR = 2.55, 95%CI: 1.04--6.29; P~heterogeneity~ = 0.002), pancreatic cancer (HR = 2.53, 95%CI: 1.82--3.51; P~heterogeneity~ = 0.003) and liver cancer (HR = 1.93, 95%CI: 1.39--2.69; P~heterogeneity~ = 0.688); a worse DFS in lung cancer (HR = 2.05, 95%CI: 1.32--3.18; P~heterogeneity~ = 0.839) and pancreatic cancer (HR = 2.87, 95%CI: 1.89--4.35; P~heterogeneity~ = 0.524); a poorer RFS/CSS in GI cancers (HR = 2.5, 95%CI: 1.1--5.71; P~heterogeneity~ = 0.005), lung cancer (HR = 2.25, 95%CI: 1.57--3.23; P~heterogeneity~ = 0.605) and prostate cancer (HR = 2.04, 95%CI: 1.17--3.54; P~heterogeneity~ = 0.957).

In the subgroup analyses by ethnicity, we found that no matter the cases were Asian or Caucasian, the high expression of miR-21 was still a significantly poor predictor for OS (Asian: HR = 2.19, 95%CI: 1.76--2.73; P~heterogeneity~\<0.001; Caucasian: HR = 1.86, 95%CI: 1.46--2.37; P~heterogeneity~\<0.001), DFS (Asian: HR = 1.62, 95%CI: 1.06--2.47; P~heterogeneity~ = 0.008; Caucasian: HR = 1.37, 95%CI: 1.07--1.76; P~heterogeneity~ = 0.006) and RFS/CSS (Asian: HR = 2.17, 95%CI: 1.52--3.09; P~heterogeneity~ = 0.322; Caucasian: HR = 2.1, 95%CI: 1.34--3.27; P~heterogeneity~ = 0.065).

Further analyses of studies evaluating OS by sample type also revealed that high expression of miR-21 remained to be a worse prognostic marker regardless of sample source (tissue sample: HR = 1.87, 95%CI: 1.61--2.16; P~heterogeneity~\<0.001; circulation sample: HR = 2.06, 95%CI: 1.42--2.99; P~heterogeneity~ = 0.008). In addition, high miR-21 in FFPE (HR = 1.68, 95%CI: 1.29--2.18; P~heterogeneity~\<0.001) and frozen tissue (HR = 1.99, 95%CI: 1.59--2.49; P~heterogeneity~\<0.001) showed consistent results. Pooled results of 8 studies that explored serum miR-21 also revealed negative prognostic role of increased miR-21 (HR = 1.94, 95%CI: 1.25--3.03; P~heterogeneity~ = 0.003)

A total of seven studies [@pone.0102413-Markou1], [@pone.0102413-Giovannetti1], [@pone.0102413-Hwang1], [@pone.0102413-Voortman1], [@pone.0102413-Jiang1], [@pone.0102413-Markou2] investigated the prognostic role of miR-21 in the patients who received adjuvant therapy which yielded a significantly pooled HR of 2.4 (95%CI: 1.18--4.9; P~heterogeneity~\<0.001).

Publication bias {#s3c}
----------------

Begg\'s funnel plot and the Egger\'s linear regression test were used to assess publication bias. However, the funnel plots were asymmetric and the P values of Egger\'s test for OS, DFS and RFS/CSS were \<0.001, 0.011 and 0.003, respectively. Thus, a trim and fill method was conducted and pooled HRs were recalculated with hypothetically non-published studies to evaluate the asymmetry in the funnel plots. The recalculated HRs did not change significantly for OS (HR = 1.61, 95%CI: 1.41--1.83; P~heterogeneity~\<0.001;[Figure 3](#pone-0102413-g003){ref-type="fig"}) and RFS/CSS (HR = 2.01, 95%CI: 1.54--2.77; P~heterogeneity~ = 0.018). But the prognostic role of high expression of miR-21 for DFS was weaken with a recalculated HR of 1.11 (95%CI: 0.9--1.38; P~heterogeneity~\<0.001).

![Funnel plot adjusted with trim and fill method for overall survival.\
Circles: included studies. Diamonds: presumed missing studies.](pone.0102413.g003){#pone-0102413-g003}

Discussion {#s4}
==========

MiR-21, a well-known onco-miR, is up-regulated in most malignancies. Acting on various target genes such as PTEN [@pone.0102413-Bao1] and PDCD4 [@pone.0102413-Zhou1], miR-21 plays an important role in the process of cell proliferation, migration, invasion, drug resistance [@pone.0102413-Roy1] and so on. It has been reported that miR-21 could regulate Ras/MEK/ERK pathway so to influence the tumor formation. Moreover the incidence of lung tumors is higher in miR-21 overexpression mice, while lower in miR-21 knockout mice [@pone.0102413-Hatley1]. Additionally, miR-21 has been proposed as a marker of cancers for diagnosis in circulation [@pone.0102413-Asaga1], [@pone.0102413-Tsujiura1], stool [@pone.0102413-Wu1] and sputum [@pone.0102413-Yu1], prediction in therapy response [@pone.0102413-Gao3] and prognosis of patients.

Nair et al. [@pone.0102413-Nair1] systematically reviewed and synthesized that miRNAs showed promising associations with outcomes of various cancers. As the first meta-analysis [@pone.0102413-Fu1] of miR-21 related to outcomes of various cancers, Fu et al. retrieved 17 studies and found higher level of miR-21 might be associated with poorer clinical outcome, especially in subgroup of head and neck squamous cell carcinoma and digestive carcinoma. Recently, Wang et al. [@pone.0102413-Wang3] analyzed the value of circulating miR-21 and yielded a conclusion that circulating miR-21 might act as a significantly prognostic biomarker but not be suitable for a sensitive diagnostic biomarker. However, the number of studies included in these analyses was relatively small and the obtained results might not be powerful. In terms of this, we performed this updated meta-analysis including 63 articles and demonstrated that high expression of miR-21 was a significant marker for predicting worse outcomes of various cancers (HR was 1.91, 2.2 and 1.42 for OS, RFS/CSS and DFS, respectively). Subgroup analyses revealed that high expression of miR-21 could predict a worse OS in GI tumors, pancreatic cancer, lung cancer, breast cancer and liver cancer, a worse DFS in pancreatic cancer and lung cancer and poor RFS/CSS in GI tumors, lung cancer and prostate cancer. Regardless of the ethnicity background or sample source, high expression level of miR-21 was a significantly negative prognostic marker for various malignancies. As publication bias was observed, a trim and fill method was adopted to calculate the adjusted HRs. The results for OS and RFS/CSS did not change, but the results for DFS were altered.

Recently, many studies demonstrated that miRNAs including miR-21 had great potential as biomarkers for various cancers. However, several problems should be well solved before utilizing them as diagnostic or prognostic biomarkers in the clinical. As is known, non-invasive circulation sample (plasma/serum) or body fluid sample could be obtained more conveniently than tissue sample. However, studies using different types of samples may yield different results [@pone.0102413-Liu2]. Tsujiura et al. [@pone.0102413-Tsujiura1] found that some individuals might even have opposite tendency of the expression levels of miRNAs in tumor tissue and plasma. Now, many studies have investigated the clinical impact of miRNAs from exosomes which were small membrane vesicles containing proteins and nucleotides [@pone.0102413-Tanaka1]. In our study, it is pleasing that high expression of miR-21 in the tissue (FFPE/frozen tissue) or circulation both predicted poor outcomes. Thus, we might assume that patients with high expression of miR-21 from any type of sample might suffer worse clinical outcomes. Yet, normalization among different studies was not consistent. The internal controls used for tissue samples are relatively consistent ranging from U6 to U44, while there is no consensus on suitable small RNA reference genes for circulation or body fluid sample. MiR-16 was used as a reference gene in some studies [@pone.0102413-Le1], [@pone.0102413-Liu4]. But the optimal way for miRNA normalization in circulation or body fluid sample is probably the spiked-in normalization method [@pone.0102413-Kroh1]. Therefore, future studies focusing on the consistent normalization are warranted. In addition, as biomarkers, a panel of miRNAs might be more sensitive and specific than a single miRNA [@pone.0102413-MarAguilar1], [@pone.0102413-Li4]. The combination of miR-21 and some specific miRNAs might elevate its predictive power. Finally, methods for detecting miRNAs were diverse, among which RT-PCR was one of the most widely used approaches. Nevertheless many new methodologies emerged, such as the next-generation sequencing approach [@pone.0102413-Yang1] and the electrochemical approach [@pone.0102413-Lusi1]. In short, a proper method for clinical application should be less expensive, reproducible, stable and with high sensitivity and specificity. Accordingly, great efforts should be made in the future to apply miRNAs including miR-21 as reliable biomarkers in the clinical.

Several limitations of this study should be considered. First, the studies retrieved in our study were limited in English, which might partially contribute to the observed publication bias. By conducting the trim and fill method, we found that the pooled results did not change significantly except for DFS. Thus, attention should be paid to the prognostic role of miR-21 for DFS. Second, different countries, cancer types, methods and other variables might contribute to the relatively large heterogeneity in this study. Third, the number of studies investigating some special types of cancer was small. For instance, there was only one study focusing on mesothelioma [@pone.0102413-Busacca1]. More studies on these cancers are needed in the future.

In conclusion, the evidence from the meta-analysis revealed that high expression level of miR-21 was a negative predictor for survival in various cancers, especially for OS and RFS/CSS. However, our results should be considered with caution due to the limitations listed above. To better understand and use miRNAs as biomarkers in the clinical, more large-scale and standard investigations are worth conducting.
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